Watson’s Concerta REMAINS Approvable and 4 Stocks Enjoying 52-Week Highs
The Spectranetics (NASDAQ:SPNC) raises its FY12 revenue view to $137 million to $139.5 million from $133.5 million to $136.5 million, consensus $136.38 million. The shares closed at $11.98, up $1.83 or 18.03% on the day. They have traded in a 52-week range of $5.16 to $11.89.
Sun Communities (NYSE:SUI) reports a Q2 FFO of 78c, consensus 78c. The shares closed at $46.00, down $0.34 or 0.73% on the day. They have traded in a 52-week range of $30.49 to $46.83.
Ventas (NYSE:VTR) reports a Q2 normalized FFO of 95c, consensus 92c. The shares closed at $65.72, up $0.35 or 0.54% on the day. They have traded in a 52-week range of $43.25 to $66.03.
Wal-Mart Stores (NYSE:WMT) faces a lawsuit from disability rights advocates, accusing the retailer of not making payment machines accessible to disabled customers in wheelchairs and scooters, reports Reuters. The shares closed at $73.67, up $1.59 or 2.21% on the day. They have traded in a 52-week range of $48.31 to $73.46.
Watson Pharmaceutica (NYSE:WPI) states that it predicts that its Concerta application is proofable and is still approvable, and the company is having “good ongoing discussion” with FDA. However, Concerta approval “has not been a high priority item” at the moment since Watson does not require approval until the end of 2014. The company states that it does not know if there will be an entrant in 2012, but if one does come, it does not expect it to have “any major impact” on the company’s guidance. Comments taken from Q2 earnings conference call. The shares closed at $77.78, up $0.99 or 1.29% on the day. They have traded in a 52-week range of $55.00 to $78.00.
Don’t Miss: American Express Stock: Buy, Sell, or Stay Away?
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.